Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes

International Journal of Obesity

Volumn 38, Issue 10, 2014, Pages 1365-1373

  Patel, S ^a,c   Mace, O J ^a,d   Tough, I R ^b   White, J ^a,e   Cock, T A ^a,f   Berglund, U Warpman ^a,g   Schindler, M ^a,h   Cox, H M ^b  

^a Prosidion Ltd   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Heptares Therapeutics Ltd   (United Kingdom)

^e Argenta Discovery Ltd   (United Kingdom)

^f Pharmaxis Ltd   (Australia)

^g KAROLINSKA INSTITUTE   (Sweden)

^h ASTRAZENECA R AND D   (Sweden)

Author keywords

Glucagon like peptide 1; GPR119; Incretins; Intestinal responses; Peptide YY and Y1 receptors; Type 2 diabetes rodent models

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE INSULINOTROPIC PEPTIDE; INSULIN; MESSENGER RNA; N (2 HYDROXYETHYL) 4 [3 [1 (3 ISOPROPYL [1,2,4] OXADIAZOL 5 YL) PIPERIDIN 4 YL]PROPOXY] 2 METHYL BENZAMIDE; PEPTIDE HORMONE; PEPTIDE YY; UNCLASSIFIED DRUG; GPR119 PROTEIN, MOUSE; GPR119 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INSULIN RELEASE; INTESTINE LOOP; ION TRANSPORT; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SMALL INTESTINE; AGONISTS; ANIMAL; BODY WEIGHT; C57BL MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; INTESTINE MUCOSA; METABOLISM; MOUSE MUTANT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; ZUCKER RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, OBESE; PEPTIDE YY; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; THINNESS;

EID: 84930736184     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2014.10     Document Type: Article

References (42)

1. Fredriksson R, Hoglund PJ, Gloriam DE, Lagerstrom MC, Schioth HB. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett 2003; 554: 381-388.
2. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006; 3: 167-175.
3. Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007; 148: 2601-2609.
4. Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K et al. Discovery of the first potent and orally efficacious agonist of the orphan G protein-coupled receptor 119. J Med Chem 2008; 51: 5172-5175.
5. Yoshida S, Ohishi T, Matsui T, Shibasaki M. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun 2010; 400: 437-441.
6. Jones RM, Leonard JN, Buzard DJ, Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat 2009; 19: 1339-1359.
7. Katz LB, Gambale JJ, Rothenburg PL, Vanapalli SR, Vaccaro N, Xi L et al. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab 2012; 14: 709-716.
8. Chu ZL, Carroll C, Chen R, Alfonso J, Gutierrez V, He H et al. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol 2010; 24: 161-170.
9. Flock G, Holland D, Seino Y, Drucker DJ. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 2011; 152: 374-383.
10. Ning Y, O'Neill K, Lan H, Pang L, Shan LX, Hawes BE, Hedrick JA. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol 2008; 155: 1056-1065.
11. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 2008; 149: 2038-2047.
12. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamideinduced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L cell. Diabetes 2009; 58: 1058-1066.
13. Sakamoto Y, Inoue H, Kawakami S, Miyawaki K, Miyamoto T, Mizuta K, Itakura M. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem Biophys Res Commun 2006; 351: 474-480.
14. Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 2009; 201: 219-230.
15. Rogers GJ, Tolhurst G, Ramzan A, Habib AM, Parker HE, Gribble FM, Reimann F. Electrical activity-triggered glucagon-like peptide-1 secretion from primary murine L-cells. J Physiol 2011; 589: 1081-1093.
16. Hansen KB, Rosenkilde MM, Knop FK, Wellner N, Diep TA, Rehfeld JF et al. 2-Oleoyl Glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab 2011; 96: E1409-E1417.
17. Sundler F, Ekblad E, Håkanson R. Localisation and colocalisation of GI peptides. In: Handbook of Experimental Pharmacology Gastrointestinal Regulatory Peptides Brown DR (ed) Springer-Verlag: Berlin, Germany, 1993; 106: pp 1-28.
18. Chan JL, Stoyneva V, Kelesidis T, Raciti P, Mantzoros CS. Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia 2006; 49: 169-173.
19. Tough IR, Forbes S, Tolhurst R, Ellis M, Herzog H, Bornstein J, Cox HM. Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y1 and Y2 receptors. Br J Pharmacol 2011; 164: 66-79.
20. Liu CD, Aloia T, Adrian TE, Newton TR, Bilchik AJ, Zinner MJ et al. Peptide YY: a potential proabsorptive hormone for the treatment of malabsorptive disorders. Am Surg 1996; 62: 232-236.
21. Cox HM, Tough IR. Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol 2002; 135: 1505-1512.
22. Batterham RL, Cohen MA, Ellis SM, Le Roux, CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948.
23. Cox HM, Tough IR, Woolston AM, Zhang L, Nguyen AD, Sainsbury A, Herzog H. Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab 2010; 11: 532-542.
24. Overton HA, Babbs AJ, Doel SM, Fyfe CT, Gardiner LS, Griffin G et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small molecule hypophagic agents. Cell Metab 2006; 3: 167-175.
25. Mace OJ, Schindler M, Patel S. The regulation of K- And L cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J Physiol 2012; 590: 2917-2936.
26. Cox HM, Pollock EL, Tough IR, Herzog H. Multiple Y receptors mediate pancreatic polypeptide responses in mouse colon mucosa. Peptides 2001; 22: 445-452.
27. Cox HM, Cuthbert AW. Neuropeptide Y antagonises secretagogue evoked chloride transport in rat jejunal epithelium. Pflugers Arch 1988; 413: 38-42.
28. Cox HM, Cuthbert AW, Håkanson R, Wahlestedt C. The effect of neuropeptide Y and peptide YY on electrogenic ion transport in rat intestinal epithelia. J Physiol 1988; 398: 65-80.
29. Tough IR, Holliday ND, Cox HM. Y(4) receptors mediate the inhibitory responses of pancreatic polypeptide in human and mouse colon mucosa. J Pharmacol Exp Ther 2006; 319: 20-30.
30. Zhang M, Feng Y, Wang J, Zhao J, Li T, He M et al. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice. PLoS One 2013; 8: e63861.
31. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
32. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
33. Brubaker PL. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinol 2010; 151: 1984-1989.
34. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
35. Drucker DJ. Minireview: The glucagon-like peptides. Endocrinology 2001; 142: 521-527.
36. Pedersen J, Ugleholdt RK, Jorgenson SM, Windelov JA, Grunddal KV, Schwartz TW et al. Glucose metabolism is altered after loss of L cells and α-cells but not influenced by loss of K cells. Am J Physiol Endocrinol Metab 2012; 304: E60-E73.
37. Lan H, Lin HV, Wang CF, Wright MJ, Xu S, Kang L et al. GPR119 agonists mediate GLP-1 secretion from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol 2012; 165: 2799-2807.
38. Cornall LM, Mathai ML, Hryciw DH, McAinch AJ. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases? Expert Opin Investig Drugs 2013; 22: 487-498.
39. Imai Y, Patel HR, Hawkins EJ, Doliba NM, Matschinsky FM, Ahima RS. Insulin secretion is increased in pancreatic islets of neuropeptide Y-deficient mice. Endocrinology 2007; 148: 5716-5723.
40. Semple G, Ren A, Fioravanti B, Periera G, Calderon I, Choi K et al. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Letts 2013; 21: 3134-3141.
41. Ansarullah Yu L, Holstein M, DeRuyter B, Rabinovitch A, Guo Z. Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor. PLoS One 2013; 8: e53345.
42. Goodman ML, Dow J, van Vliet AA, Hadi S, Karbiche D, Lockton JA. The novel GPR119-receptor agonist PSN821 shows glucose lowering and decreased energy intake in patients with T2DM after 14 days treatment. Diabetes 2011; 60: A273 (Abstract).